BridgeBio Pharma Return on Investment 2018-2023 | BBIO
Current and historical return on investment (ROI) values for BridgeBio Pharma (BBIO) over the last 10 years.
| BridgeBio Pharma ROI - Return on Investment Historical Data |
| Date |
TTM Net Income |
LT Investments & Debt |
Return on Investment |
| 2023-12-31 |
$-0.61B |
$0.38B |
-136.48% |
| 2023-09-30 |
$-0.56B |
$0.53B |
-120.28% |
| 2023-06-30 |
$-0.53B |
$0.37B |
-111.34% |
| 2023-03-31 |
$-0.46B |
$0.50B |
-83.79% |
| 2022-12-31 |
$-0.51B |
$0.46B |
-85.98% |
| 2022-09-30 |
$-0.55B |
$0.57B |
-79.71% |
| 2022-06-30 |
$-0.57B |
$0.68B |
-80.71% |
| 2022-03-31 |
$-0.58B |
$0.67B |
-76.31% |
| 2021-12-31 |
$-0.58B |
$0.84B |
-68.67% |
| 2021-09-30 |
$-0.54B |
$0.64B |
-69.29% |
| 2021-06-30 |
$-0.51B |
$0.92B |
-64.47% |
| 2021-03-31 |
$-0.54B |
$0.97B |
-71.19% |
| 2020-12-31 |
$-0.47B |
$0.58B |
-63.80% |
| 2020-09-30 |
$-0.43B |
$0.69B |
-57.65% |
| 2020-06-30 |
$-0.36B |
$0.79B |
-50.40% |
| 2020-03-31 |
$-0.31B |
$0.91B |
-58.85% |
| 2019-12-31 |
$-0.27B |
$0.57B |
-91.83% |
| 2019-06-30 |
$-0.17B |
|
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.278B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
